Dr. Reddy's Laboratories Ltd. has formally announced the schedule for releasing its Q4 and full year FY26 financial results through a regulatory filing under Regulation 30. The pharmaceutical company will unveil its financial performance for the quarter and year ended March 31, 2026, on Tuesday, May 12, 2026, following a Board Meeting.

Regulatory Filing Details

The company submitted its earnings call intimation on April 24, 2026, to all relevant stock exchanges including NSE (Stock Code: DRREDDY-EQ), BSE (Stock Code: 500124), NYSE (Stock Code: RDY), and NSE IFSC (Stock Code: DRREDDY). The notification was digitally signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.

Results Release Schedule

The company has outlined a comprehensive communication plan for the results announcement, ensuring wide accessibility across multiple platforms and stakeholders.

Earnings Call and Registration

Following the results release, Dr. Reddy's management will conduct an earnings call to discuss the company's financial performance with investors and analysts. The call is scheduled for Tuesday, May 12, 2026, at 19:30 PM IST, corresponding to 10:00 AM Eastern Time for international participants.

Interested stakeholders can pre-register for the earnings call through the company's dedicated webinar link at https://drreddys.zoom.us/webinar/register/WN_DW56_eZ6SAGF8FWL6wa-EQ . The management team will provide insights into the quarterly and annual performance, addressing key financial metrics and business developments.

Communication and Contact Details

Dr. Reddy's has designated specific contact persons for stakeholder communications. Aishwarya Sitharam handles investor relations ( aishwaryasitharam@drreddys.com ), while Priya K manages media relations ( priyak@drreddys.com ). The company will ensure comprehensive access to financial information by making press meet presentations, audio recordings, and complete transcripts available on its website for stakeholders unable to participate in live sessions.

Dr. Reddy's Laboratories has informed stock exchanges that its Board of Directors will consider a proposal for recommending final dividend for the financial year 2025-26. The pharmaceutical company issued the intimation on April 16, 2026, as a continuation of its earlier communication dated March 23, 2026.

Board Meeting Details

The board meeting has been scheduled in compliance with Regulation 29 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015. The meeting agenda includes consideration of the final dividend proposal, though the company has not disclosed specific details about the quantum or certainty of the dividend declaration.

Regulatory Compliance

The intimation was sent to multiple stock exchanges where Dr. Reddy's Laboratories shares are listed. The company maintains listings on the National Stock Exchange of India, BSE Limited, New York Stock Exchange, and NSE IFSC Ltd. The communication was signed by K Randhir Singh, who serves as Company Secretary, Compliance Officer, and Head of Corporate Social Responsibility.

Corporate Communication

The formal intimation follows standard corporate governance practices, providing advance notice to shareholders and market participants about significant board decisions. The company emphasized that the communication is for information and record purposes, maintaining transparency in its corporate actions and dividend policy considerations.